Zobrazeno 1 - 10
of 49
pro vyhledávání: '"Terrance D Barrett"'
Autor:
Scott D. Bembenek, Hariharan Venkatesan, Hillary M. Peltier, Mark D. Rosen, Terrance D. Barrett, Kimon C. Kanelakis, Heather L. Palomino, Theresa I. Brondstetter, Taraneh Mirzadegan, Michael H. Rabinowitz
Publikováno v:
ACS Omega, Vol 4, Iss 4, Pp 6703-6708 (2019)
Externí odkaz:
https://doaj.org/article/2f7bcabc827d4448a44a96c74939a085
Autor:
Tomas Ganz, Elizabeta Nemeth, Stefano Rivella, Paul Goldberg, Andrew R. Dibble, Michael L. McCaleb, Shuling Guo, Brett P. Monia, Terrance D. Barrett
Publikováno v:
Advances in Therapy. 40:1317-1333
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::30c49115c8dc1e1ffe6f76b35881f861
https://doi.org/10.1007/s12325-022-02421-w
https://doi.org/10.1007/s12325-022-02421-w
Autor:
Carol Marimpietri, Mark Crowther, Taisei Kinoshita, Juthamas Sukbuntherng, Ahmad Mokatrin, Terrance D. Barrett, Betty Chang, Joi Ninomoto, Danelle F. James
Publikováno v:
Hematology (Amsterdam, Netherlands). 25(1)
Background: Ibrutinib, a first-in-class, once-daily inhibitor of Bruton's tyrosine kinase (BTK), is approved in the US and EU for the treatment of various B-cell malignancies. In clinical studies, ...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::74be2af6a2580c5a293ce02203b96c00
https://pubmed.ncbi.nlm.nih.gov/32131714
https://pubmed.ncbi.nlm.nih.gov/32131714
Autor:
Wayne Shaw, Terrance D. Barrett, Mehul Desai, David R. Matthews, Greg Fulcher, Bruce Neal, Dick de Zeeuw, Karin Rådholm, Kenneth W. Mahaffey, Vlado Perkovic, Scott D. Solomon, Gemma A. Figtree
Publikováno v:
Circulation, 138(5), 458-468. LIPPINCOTT WILLIAMS & WILKINS
Background: Canagliflozin is a sodium glucose cotransporter 2 inhibitor that reduces the risk of cardiovascular events. We report the effects on heart failure (HF) and cardiovascular death overall, in those with and without a baseline history of HF,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::54a00bce6f16e9de8fb26e026db4b3f5
https://doi.org/10.1161/CIRCULATIONAHA.118.034222
https://doi.org/10.1161/CIRCULATIONAHA.118.034222
Autor:
Dick De Zeeuw, Wayne Shaw, Kenneth Mahaffey, Terrance D. Barrett, David R. Matthews, Bruce Neal, Gemma Figtree, Vlado Perkovic, Greg Fulcher, Karin Rådholm
Publikováno v:
68th Annual Scientific Session and Expo of the American-College-of-Cardiology (ACC)
Canagliflozin is a sodium glucose co-transporter 2 inhibitor that reduces the risk of heart failure (HF) in patients with type 2 diabetes and high cardiovascular risk. It is not known if canagliflozin has effects on both HF with preserved ejection fr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::eb17a16b7e70ad0a2165d371c745c55c
http://hdl.handle.net/10044/1/79683
http://hdl.handle.net/10044/1/79683
Autor:
Karin Rådholm, Wayne Shaw, Greg Fulcher, Vlado Perkovic, Gemma A. Figtree, Bruce Neal, Kenneth W. Mahaffey, Dick de Zeeuw, David R. Matthews, Terrance D. Barrett
Publikováno v:
Circulation, 139(22), 2591-2593. LIPPINCOTT WILLIAMS & WILKINS
Patients with type 2 diabetes mellitus are at high risk of developing heart failure (HF).1 Sodium glucose co-transporter 2 (SGLT2) inhibitors have been demonstrated, in large scale trials, to reduce the risk of HF events in patients with type 2 diabe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b522177809c9e27df4622018893e3f73
http://hdl.handle.net/10044/1/69143
http://hdl.handle.net/10044/1/69143
Autor:
Ngozi Erondu, Dick de Zeeuw, Greg Fulcher, Terrance D. Barrett, Kenneth W. Mahaffey, Bruce Neal, Michele A. Weidner-Wells, Wayne Shaw, Vlado Perkovic, Hsiaowei Deng, David R. Matthews
Publikováno v:
Lancet Diabetes & Endocrinology, 6(9), 691-704. ELSEVIER SCIENCE INC
Background In the Canagliflozin Cardiovascular Assessment Study (CANVAS) Program, canagliflozin reduced the rates of major adverse cardiovascular events and the results suggested a renal benefit in patients with type 2 diabetes who were at high risk
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4e2401da67eaf323ceea2b65c40f863b
http://hdl.handle.net/10044/1/60620
http://hdl.handle.net/10044/1/60620
Autor:
Judy Skaptason, Michael H. Rabinowitz, Terrance D Barrett, Theresa I. Brondstetter, Xiaodong Wu, Jingjin Gao, Heather L. Palomino, Hariharan Venkatesan, Jing Ying Ma, Wen Yan, Freddy Schoetens, Nigel P. Shankley, Katherine P Merton, Da-Thao Tran, Mark D. Rosen, Kimon C Kanelakis
Publikováno v:
British Journal of Pharmacology. 172:4078-4088
Background and Purpose Small-molecule inhibitors of prolyl hydroxylase (PHD) enzymes are a novel target for the treatment of anaemia and functional iron deficiency (FID). Other than being orally bioavailable, the differentiation of PHD inhibitors fro
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a7198839e8209100a3172cb9f3b9fae7
https://doi.org/10.1111/bph.13188
https://doi.org/10.1111/bph.13188
Autor:
P Wagaman, Michele C. Rizzolio, Magda F. Morton, L Andries, Terrance D Barrett, Nigel P. Shankley, Guy Lagaud, W Yan, JM Freedman
Publikováno v:
British Journal of Pharmacology. 166:1684-1693
BACKGROUND AND PURPOSE JNJ-26070109 [(R)4-bromo-N-[1-(2,4-difluoro-phenyl)-ethyl]-2-(quinoxaline-5-sulfonylamino)-benzamide] is a novel antagonist at cholecystokinin CCK2 receptors with good pharmacokinetic properties and represents a novel mechanism
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::05d41c3454e984aed76f96fbe7de05c7
https://doi.org/10.1111/j.1476-5381.2012.01878.x
https://doi.org/10.1111/j.1476-5381.2012.01878.x
Publikováno v:
Trends in Pharmacological Sciences. 32:201-205
Gastrin, acting through peripheral cholecystokinin (CCK) 2 receptors, is a major hormonal regulator of gastric acid secretion. The effects of gastrin on acid secretion occur both acutely and chronically because gastrin directly stimulates gastric aci
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0a46cd19c055dd2b8791b9a02db15a51
https://doi.org/10.1016/j.tips.2011.02.003
https://doi.org/10.1016/j.tips.2011.02.003